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profiles of peripheral blood mono-
nuclear cells to determine IFN signa-
tures. Across the 16 different skin
conditions there was an inverse
correlation between IFN-b and IFN-g,
notably with particular diseases
mapping to reproducible ratios—and
thus offering molecular signposts to dis-
ease diagnostics. Collectively, the data
provide valuable insight into the mole-
cular processes that underlie various
diseases and furthermore infer that simi-
lar processes underpin diseases from the
same disease classifier.
Multi-disease classifiers, disease
classification, and the development of
personalized medicine
The core ethos underpinning the con-
cept of personalized medicine is ‘‘right
patient, right drug, right dose, at the
right time’’. The integrative molecular
classification, as well as the functional
analysis, outlined in the study by Inkeles
et al. (2014), offers a valuable tool in
bringing personalized medicine closer
to the clinical frontline. Although it is
tempting to jump ahead and speculate
about how multi-disease classifiers
could be used to identify novel
biomarkers and therapeutic targets for
skin diseases, the current emphasis has
to be on improving understanding of
disease pathogenesis, implementing best
clinical practice, and reflecting on
whether current knowledge on disease
classification and pathophysiology is
matched by the multi-disease classifier
data. Dermatology, and medicine in
general, is littered with inappropriate
(or frankly wrong) disease sub-
groupings. For example, 150 years ago
epidermolysis bullosa and urticaria were
thought to be similar diseases, and even
in current practice, we still categorize
different keratin genodermatoses as
either mechanobullous diseases or
forms of ichthyosis, despite the well
characterized shared pathogenic
overlap of keratin intermediate filament
mutations and keratinocyte cytolysis. For
inflammatory dermatoses, the dermato-
logical literature contains numerous
reports of imprecise entities such as
‘‘psoriasiform eczema’’ or ‘‘eczematoid-
lichenoid eruption’’, but the data mining
approach advocated by Inkeles et al.
(2014) has the potential to help resolve
such issues, or at least offer fresh insight
into discrete or shared disease pathogen-
eses. However, perhaps stories of
common disease pathogenesis only
tend to become more relevant when
therapies are introduced or challenged.
The multi-disease classifier data presen-
ted by Inkeles et al. (2014) offer both a
reality check and a glimpse into how
personal diagnostics and therapeutics
might develop. The study also high-
lights the considerable resources on
gene expression data that are freely
accessible in the public domain, and
the value of thinking beyond the traditio-
nal disease-control experiment. There
remains a rich seam of widely avai-
lable skin disease gene signature data
still available to mine, with significant
potential benefits in store for the future
classification and improved treatment of
diseases in dermatology.
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Healing Refractory Venous Ulcers:
New Treatments Offer Hope
Robert S. Kirsner1, Katherine L. Baquerizo Nole1, Joshua D. Fox1 and
Sophia N. Liu1
Non-healing wounds are associated with an inflammatory and proteolytic wound
environment, and recent therapeutic strategies have been focused on reversing
these changes. Connexins, as members of gap junctions, are important in
intercellular signaling and wound repair. Connexin 43 (Cx43) downregulation is
associated with normal wound healing, and it has been found to be upregulated
in non-healing venous leg ulcers (VLUs). Ghatnekar et al. (2014) report findings of
a small phase II trial performed in Indian patients with chronic VLUs, reporting
that ACT1, a mimetic peptide of Cx43, accelerates healing in the treatment group.
Despite standard care with compression therapy and adjuvant therapy for
refractory wounds, at present in clinical practice a significant number of
patients remain unhealed. The potential for ACT1 exists to help heal refractory
VLUs, but it faces additional regulatory hurdles.
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Over a quarter of patients with venous
leg ulcers (VLUs) fail to heal with
standard care, and even those who
do heal often take 6 months or
longer to do so (de Araujo et al.,
2003). New treatments for VLUs
are needed. In this issue of the Journal
Ghatnekar et al. (2014) describe a novel
treatment that employed ACT1 (First
String Research, Mt Pleasant, SC)––a
connexin 43 (Cx43) peptide mimetic of
the carboxyl-terminus of Cx43.
Although this study shows promise
(Ghatnekar et al., 2014), it is important
to put these results into context by
reviewing where we are and where we
are going in treating VLUs.
The importance of VLUs
VLUs are the most common cause of leg
ulcers, affecting up to 1% of all adults
and 3% of older adults because of its
increasing incidence and prevalence
with advancing age. The average annual
incidence rate of VLU is 2.2% in
Medicare aged populations and 0.5%
in younger patients (Rice et al., 2014).
VLUs are associated with impaired
venous return, caused by calf muscle
pump dysfunction. This is most often
due to obstruction or valvular dysfunc-
tion affecting superficial, perforator,
or deep veins, and it leads to sustained
ambulatory venous pressures (also known
as venous hypertension; Figure 1). As a
result, patients develop edema and slow
healing wounds, most commonly, on their
lower legs or ankles (Yim et al., 2014).
Accounting for upward of 90% of leg
ulcers, VLUs are associated with reduced
quality of life (QOL) and increased health-
care costs. For example, recent data for
both young (privately insured) and older
(Medicare insured) patients with VLUs
indicate that patients with VLUs utilize
significantly more medical resources
and have increased annual incremental
medical costs compared with matched
patients without VLUs (Rice et al.,
2014). Working patients with VLUs
missed more days from work, resulting
in substantially higher work-loss costs.
Not only is QOL reduced in patients
with VLUs, treatment improves health-
related QOL (Salome et al., 2014). After
excluding concomitant significant arterial
disease, standard care most often
employs multilayered compression
wraps, which are intended to reverse
the pathogenic mechanism. Effective
compression therapy results in healing
in up to three quarters of patients with
VLUs, especially in those with small
ulcers that are of short duration.
Approach to standard and adjuvant care
of VLUs
Clinical guidelines encourage a 4-week
trial of standard care, and, if significant
reduction in wound size does not
occur (40% in typical ulcers o10 cm2)
during this time, adding adjuvant care to
compression therapy is recommended
(Tang et al., 2012). Data from rando-
mized control trials for commercially
available products suggest adding oral
agents, such as Pentoxifylline (up to
800 mg three times daily) or Aspirin, or
topically applied cell and tissue-based
products, such as cellular products,
including a bilayer living skin equiva-
lent (Apligraf, Organogenesis, Canton,
MA) or acellular constructs such as
porcine small intestine submucosa
(Oasis, Smith and Nephrew, Largo, FL)
or poly-N-acetyl glucosamine isolated
from microalgae (pGIcNAc, Talymed,
Marine Polymer Technologies,
Danvers, MA). A recent comparative
effectiveness study found better healing
with a bilayer living skin equivalent
compared with the porcine small
intestine submucosa in clinical practice
Clinical Implications
 Despite appropriate standard of care including multilayered compression
wrappings, more than a quarter of patients with VLUs fail to heal.
 Connexin 43 (Cx43), a component of gap junctions, has an important role
in many aspects of wound healing, and Cx43 is upregulated in wound
edges of nonhealing VLUs.
 ACT1, a mimetic peptide of Cx43, in a Phase 2 study accelerated healing of
refractory VLUs compared with a regimen of standard of care.
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Figure 1. Calf muscle pump and venous insufficiency. Venous blood return to the heart results from
venous blood flowing from the SVS to the DVS via the action of the calf muscle pump. At rest in the
standing position, the hydrostatic pressure in the SVS and DVS systems is approximately 80 mm Hg and
net flow equals 0. (a) Muscle contraction during ambulation. With full range of movement (ROM) of the
ankle during ambulation and resultant contraction of the gastrocnemius and soleus muscles, a pressure
480 mm Hg is exerted on the DVS and venous blood flows cephalad, whereas the SVS and CV valves
close to prevent retrograde flow into the SVS. (b) Muscle relaxation in ambulation. With relaxation of calf
muscles following the emptying of the DVS, pressure therein decreases below 80 mm Hg and blood from
the SVS empties into the DVS through the patent SV and CV valves. A combination of pathologies may
occur resulting in venous insufficiency. SVS or CV valve dysfunction, calf muscle failure, decreased ROM
at the ankle, DVS outflow obstruction, and DVS valve dysfunction can all cause venous hypertension or
more appropriately termed sustained ambulatory venous pressures (venous pressure that does not reduce
with walking). CV, communicating veins; DVS, deep venous system; SV, superficial veins; SVS, superficial
venous system. Arrows toward DVS, calf muscle contraction; arrows away from DVS, calf muscle
relaxation. Blue arrows, venous flow.
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(Marston et al., 2014). Topical growth
factors to speed up healing of VLUs are
not available commercially, but intra-
lesional injection of GM-CSF, available
as a hematopoiesis stimulant, was
effective in healing VLUs as an adju-
vant to compression in a phase II trial.
Nonetheless, its use is limited by local
and systemic (bone) pain associated
with injections (Richmond et al., 2013;
Table 1).
Despite a long history of venous
surgical interventions to speed up VLU
healing, data to date do not demonstrate
improved healing of existing ulcers, but
they do suggest a decrease in both
severity and rates of recurrence after
surgical intervention (Gohel et al.,
2007). More invasive surgery with high
complication rates have been replaced
by less invasive percutaneous proce-
dures such as radiofrequency, endovas-
cular laser ablation, and ultrasound
guided foam sclerotherapy. Enthusiasm
exists for these procedures, and time
will tell whether clinical data match
that enthusiasm (Siribumrungwong
et al., 2012).
New strategies for refractory VLUs
A number of technologies are currently
under investigation for treating VLUs;
cell-based therapies are farthest along,
in phase III studies. HP-802 (Smith and
Nephew, Fort Worth, TX) is a novel
therapy of spray applied cell therapy
containing growth arrested allogeneic
neonatal keratinocytes and fibroblasts.
phase II dose finding studies have found
an optimal dose and a statistical and
clinical benefit with increased and faster
healing when given every 14 days via a
spray technology (Kirsner et al., 2012).
Another technology, allogeneic white
blood cells delivered by periodic intra-
lesional injection (CureXcell, Macrocure,
Petach Tikva, Israel), which has been
used extensively in Israel, based on
non-randomized control data, is now
being studied in the United States in a
phase III trial (Zuloff-Shani et al., 2010).
Given this background information,
we address new data for ACT1. Ninety-
two Indian patients with refrac-
tory VLUs were randomized to one of
the two parallel groups––either weekly
ACT1 gel formulation application
plus four-layer compression bandage
therapy or four-layered compression.
The use of ACT1 was associated
with a significantly greater reduction in
mean percent ulcer area during the
12-week study (79 vs. 36%, P¼ 0.02)
and greater wound closure at week 12
(57 vs. 28%, P¼ 0.006). No safety
concerns were noted, albeit it was a
small phase II trial.
Rationale for new strategies for VLU
treatment
Why venous ulcers fail to heal despite
adequate compression is not known.
What is known is that with prolonged
non-healing of wounds, cellular and
molecular changes occur within the
wound bed and at wound edges
(Charles et al., 2008). An inflammatory
and proteolytic wound environment,
coupled with molecular changes at
the wound edges likely contribute to
poor healing. Reversing these changes
represents a ‘‘therapeutic opportunity.’’
Connexins are the channel-forming
component of gap junctions (GJs)
that allow small molecule exchange
(o1000 Da) and facilitate signaling
and electrical impulse propagation.
Given the importance of GJs, it would
be expected that Connexins, including
Cx43, would have many functions, in
all phases of wound healing (and espe-
cially during the inflammatory and
proliferative phases). Cx43 has critical
roles in regulating the inflammation,
edema, and fibrosis that follow tissue
injury. During normal wound healing,
Cx43 downregulation is correlated
with increases in transforming growth
factor-b mRNA and collagen a-1 and
with decreases in chemokine ligand-2
and tumor necrosis factor-a expression.
Cx43 downregulation thereby promotes
angiogenesis, fibroblast migration, kera-
tinocyte proliferation, and migration,
and it decreases the number of infiltrat-
ing neutrophils and macrophages at
sites of wounding (Mori et al., 2006).
In chronic VLUs, Cx43 is upregulated
abnormally at the epidermal wound
margins (Mendoza-Naranjo et al.,
2012). ACT1 is a 25aa peptide contain-
ing the carboxy-terminal PDZ-binding
domain that selectively inhibits Cx43,
independent of Cx43 expression,
affecting Cx43 hemichannels (Ghatnekar
et al., 2009). Hemichannels provide a
paracrine route for intercellular signaling
and communication and, as a result,
regulate wound-healing processes asso-
ciated with inflammation, edema, and
fibrosis. Reduction in Cx43 hemi-
channel activity tempers inflammatory
responses, shortens the inflammatory
phase, and potentially improves healing.
Targeting Cx43 with polynucleotide
antisense DNA has led to accelerated
fibroblast migration and proliferation
(Mendoza-Naranjo et al., 2012).
Clinical potential of ACT1 and pitfalls of
phase III trials
Although the data for ACT1 are exciting,
development of a new treatment, espe-
cially using drugs, is a rigorous process.
Only 1 out of every 5,000 pharmaceutical
compounds evaluated reach United States
Food and Drug Administration approval,
and only about one in four drugs that is
successful in phase II trials gains approval
after successful completion of phase III
trials. High costs and large amounts of
time are invested, with development costs
for a drug containing a novel new che-
mical entity estimated to be between
$600 and $800 million dollars (Maderal
et al., 2012). While this cost reflects not
only direct costs of the development of
the drug and clinical trials, it also includes
the development costs of failures; costs for
a typical phase III trial for VLU is
expensive, between $5 and $15 million.
As a result, start-up companies may find
funding of well-done studies to be
problematic. Failure to appreciate trial
costs can lead to under-budgeting and
fiscal stress, as trials last longer and cost
more than is commonly predicted. Often,
under-budgeting is a consequence of
taking the most optimistic opinions
regarding patient enrollment. When this
occurs, poorly selected clinical sites may
be recruited, and, after the study begins,
inclusion and exclusion criteria tend to be
modified to speed up enrollment, often
leading to less homogenous and perhaps
inappropriate populations and perhaps a
less rigorous standard care being applied.
This can affect the quality of the study,
and it favors finding no difference in
outcomes between treatment groups.
Therefore, instead of studying a discrete
subset of patients most likely to benefit,
industry sponsors may broaden the
inclusion criteria on the basis of
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pragmatic or even market considerations
as opposed to scientific rationale.
Summary
Novel treatments for VLUs are needed.
Algorithms of care exist for the manage-
ment of patients with VLUs, but still a
significant subset of patients have ulcers
that remain unhealed. As non-healing
wounds are associated with an inflam-
matory and proteolytic wound environ-
ment, recent strategies have been
focused on reversing these changes.
Cx43 downregulation is associated with
normal wound healing, and it has been
found to be upregulated in non-healing
VLUs. Results of the use of ACT1, a
mimetic peptide of Cx43, in the treat-
ment for refractory VLUs hold promise.
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